Emerging Therapeutics in the Fight Against EV-D68
Author Information
Author(s): Kalam Nida, Balasubramaniam Vinod R. M. T.
Primary Institution: Jeffrey Cheah School of Medicine and Health Sciences Monash University Malaysia
Hypothesis
The review explores current advancements in antiviral therapies and potential therapeutics to mitigate the impact of EV-D68 infections.
Conclusion
There are currently no FDA-approved antiviral treatments or vaccines for EV-D68, highlighting the urgent need for effective therapeutic strategies.
Supporting Evidence
- EV-D68 has been linked to outbreaks of acute flaccid myelitis in children.
- Current antiviral treatments for EV-D68 are lacking, necessitating ongoing research.
- WIN-like compounds have shown potential but faced issues with resistance and side effects.
Takeaway
EV-D68 is a virus that can make kids very sick, and scientists are trying to find medicines to help fight it because there are no approved treatments yet.
Methodology
This is a review article summarizing various therapeutic strategies and research findings related to EV-D68.
Limitations
The lack of FDA-approved treatments and the rarity of acute flaccid myelitis complicate clinical trials.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website